



DEVELOPMENT, *IN-VITRO* AND *IN-VIVO*
EVALUATION OF GENTAMICIN AND NIGELLA
SATIVA OIL PLGA MICROSPHERES

BY

AHMAD FAHMI HARUN ISMAIL

A thesis submitted in fulfilment of the requirement for the
degree of Doctor of Philosophy in Pharmaceutical Sciences
(Pharmaceutical Technology)

Kulliyyah of Pharmacy
International Islamic University Malaysia

SEPTEMBER 2017

ABSTRACT

Introduction: Antibiotics are amongst the highly studied and researched candidates for sustained drug release formulation. In this current study, gentamicin was formulated in the form of microspheres using poly(lactic-co-glycolic acid) (PLGA) to be used as prophylactic approach in eradicating osteomyelitic condition in rabbits. Together with *Nigella sativa* oil (NSO) where its potentials are well known, the ability of the PLGA microspheres loaded with gentamicin and NSO was evaluated for *in-vitro* and *in-vivo* studies.

Objective: The main objective of this study was to formulate a sustained release microspheres containing gentamicin and NSO intended to treat osteomyelitis.

Methodology: Gas chromatography mass spectrometry (GC-MS), high performance liquid chromatography (HPLC), Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), thin layer chromatography (TLC) and cell viability study (MTT assay) were utilized to evaluate the compatibility as well as the stability for pre and post gamma irradiation. 27 formulations for both gentamicin and NSO microspheres were fabricated. Other than observing the external morphology of the microspheres using scanning electron microscope (SEM), the size distributions were also being analyzed. For quantification purposes, two method validations were completed by using UV-spectrophotometry following the requirements listed under ICH Q2 (R1) guidelines. For the *in-vivo* study, 16 White New Zealand rabbits were divided into 4 groups (Control, Gentamicin, NSO and Fusion) before the osteomyelitic condition was induced in the tibiae of the animals. The compressed selected microspheres were administered *in-situ* and all the animals were closely monitored for any physiological changes over a course of 6 weeks. X-ray images, hematological evaluation (white blood cell differentiations) and post surgical bacterial culture were evaluated to confirm the prophylactic ability of the microspheres to halt the infection.

Results: The size distribution ranging from 463.67 nm \pm 52.54 to 4602 nm \pm 113.58 and 409.67 nm \pm 37.45 to 6568.00 nm \pm 147.22 for gentamicin and NSO microspheres respectively. Five best formulations from gentamicin and NSO microspheres with the highest drug loading capacity (ranging from 67.32% \pm 3.18 to 83.39% \pm 4.22 for gentamicin microspheres and from 62.94% \pm 4.84 to 73.42% \pm 2.14 for NSO microspheres) were further analysed for the *in-vitro* release profile over a course of 4 weeks study. The best formulation was selected from gentamicin microspheres and NSO microspheres based on the *in-vitro* release data before being used for *in-vivo* study (compressed microspheres from formulation 6 for both gentamicin and NSO group).

Conclusion: Based on the data collected with 95% confidence level ($p < 0.05$), gentamicin and NSO microspheres indicated the ability to treat osteomyelitis when compared to the untreated group. The replacement of current conventional treatment using PMMA beads is possible by the microspheres fabricated.

خلاصة البحث

المقدمة :علم ايتاء الدواء هو علم دائم التطور رغم كل المعوقات التي تحد من نجاحه. يتطلب ايتاء الدواء في العصر الحالي تحقيق ثلاثة اهداف عامة: حماية الدواء اثناء وصوله الى المنطقة المستهدفة، امكانية تأمين افضل فعالية مع اقل سمية اضافة الى افضل مطاوعة من قبل المريض تجاه الدواء. تعتبر المضادات الحيوية من اكثر الادوية المناسبة لتطويرها بشكل مطول التأثير. في ههذ الدراسة تم تطوير الجنتاميسين بشكل ميكروسفيرات باستخدام بوليمير PLGA لكي يتم استخدامها وقائيا ضد انتان العظام عند الارانب. مع زيت الحبة السوداء المعروف بميزاته المتعددة، تم تقييم فعالية الميكروسفيرات المحملة بالزيت مع الجنتاميسين في الزجاج وفي الحي. تم استخدام اشعة غاما لتعقيم المنتج والمواد الاولية قبل الاستخدام في الحي. لتقييم التوافق والثباتية قبل وبعد الاشعة تم استخدام عدة تقنيات مثل GC-MS، HPLC، FTIR، DSC، TLC، MTT. تم تحضير 27 تحضيرة من ميكروسفيرات الجنتاميسين والزيت ودراستها من ناحية المظهر الخارجي باستخدام المجهر الالكتروني الماسح وقياس الابعاد. تراوح قياس الابعاد بين $463.67 \text{ nm} \pm 52.54$ الى $4602 \text{ nm} \pm 113.58$ و $409.67 \text{ nm} \pm 37.45$ الى $6568.00 \text{ nm} \pm 147.22$ لميكروسفيرات الجنتاميسين والزيت على التوالي. من اجل متابعة دراسة التحرر في الزجاج خلال 4 اسابيع تم اختيار 5 افضل تحضيرات والتي امتلكت اعلى نسبة تحميل (تراوحت بين $67.32\% \pm 3.18$ الى $83.39\% \pm 4.22$ لميكروسفيرات الجنتاميسين و $62.94\% \pm 4.84$ الى $73.42\% \pm 2.14$ لميكروسفيرات زيت الحبة السوداء). من اجل التحليل الكمي تم تطوير طريقتين باستخدام UV-spectrophotometry وتقييمهما حسب توصيات ICH Q2 (R1). ومن اجل الدراسة في الحي تم اختيار افضل التحضيرات وفقا لدراسة التحرر في الزجاج. تمت الدراسة على 16 ارنب نيوزلندي قسمت الى 4 مجموعات (شاهد، جنتاميسين، زيت الحبة السوداء والمزيج من الاثنين) قبل تحريض حالة انتان عظمي في عظم الظنبوب. تم اعطاء الميكروسفيرات المضغوطة اعطاء موضعيا ومراقبة جميع الحيوانات عن كثب خلال مدة 6 اسابيع لملاحظة اية تغيرات فيزيولوجية. تم تقييم صور اشعة اكس، التقييم الدموي (تمايز الكريات البيض) والزرع الجرثومي بعد الجراحة لتأكيد القدرة الوقائية للميكروسفيرات لايقاف الانتان. بناء على النتائج التي تم الحصول عليها هناك ثقة كبيرة بان ميكروسفيرات الجنتاميسين وزيت الحبة السوداء يمكن ان توفر بديلا لمعالجة انتان العظام في المستقبل.

ABSTRAK

Pengenalan: Antibiotik adalah salah satu ubatan yang sangat dikaji dalam menambahbaikan proses penghantaran di dalam badan kita. Dalam kajian ini, gentamicin diformulakan dalam bentuk butiran mikro dengan menggunakan poly(lactic-co-glycolic acid) (PLGA) untuk digunakan sebagai rawatan bagi penyakit osteomyelitis. Keupayaan butiran mikro ini yang diformulakan bersama minyak *Nigella sativa* (NSO) terus dikaji sehingga ke tahap *in-vitro* dan *in-vivo*.

Objektif: Objektif utama peyelidikan ini adalah untuk formulasikan satu bentuk rawatan bagi penyakit osteomyelitis dengan menggunakan mikrosfera mengandungi gentamicin dan NSO yang mampu melepaskan kandungannya secara perlahan-lahan.

Kaedah: Radiasi gamma diperlukan untuk menyahkuman produk yang akan digunakan bagi kajian *in-vivo*. Atas sebab ini, beberapa pendekatan pengkajian telah digunakan seperti kromatografi gas (GC-MS), kromatografi cecair berkemampuan tinggi (HPLC) dan penilaian kelangsungan sel (MTT assay) untuk menilai kesan radiasi gamma ke atas bahan mentah yang digunakan. Hanya 5 formulasi terbaik yang dipilih berdasarkan nilai kadar pengisian ubatan tertinggi sebelum hanya 1 formulasi (formulasi 6 dari kedua-dua kumpulan) yang terpilih yang akan dikaji lebih mendalam dari skop *in-vivo*. 16 arnab putih New Zealand telah didedahkan dengan kuman untuk mendapatkan kesan jangkitan kuman semisal osteomyelitis. Arnab-arnab ini dipecahkan kepada 4 kumpulan (kawalan, gentamicin, NSO dan Fusion) sebelum rawatan diberikan. Jangkitan kuman ke atas arnab-arnab tersebut dibuat ke dalam tulang tibia sebelum rawatan dengan menggunakan butiran mikro yang dimampatkan diberikan. Imej sinar-X, kadar pengiraan sel darah putih dan juga pengkulturan bakteria selepas pembedahan telah digunakan untuk menilai kadar keupayaan rawatan yang diberikan.

Keputusan: 27 formulasi butiran mikro telah dibuat dan keadaan luaran butiran tersebut dinilai dengan menggunakan mikroskop pengimbasan elektron (SEM) selain taburan saiz dan kadar pengisian ubatan turut dinilai. Taburan saiz sekitar 463.67 nm \pm 52.54 ke 4602 nm \pm 113.58 dilihat untuk gentamicin; dan 409.67 nm \pm 37.45 ke 6568.00 nm \pm 147.22 dapat dilihat untuk butiran mikro NSO. Butiran mikro tersebut terus dikaji dan dinilai dengan melihat kepada kadaran pelepas ubatan untuk kajian selama 4 minggu.

Kesimpulan: Daripada data terkumpul, amat jelas kelihatan di mana rawatan yang diberikan berkesan untuk menghalang berlakunya jangkitan kuman di dalam tibia arnab tersebut yang boleh merebak menjadi osteomyelitis. Kami percaya butiran mikro yang diformulasikan ini mampu memberi satu pendekatan alternatif dalam merawat jangkitan kuman pada tulang dan menjadi salah satu rawatan yang berkesan pada masa hadapan.

APPROVAL PAGE

The thesis of Ahmad Fahmi Harun Ismail has been approved by the following:

Farahidah Mohamed
Supervisor

Mohd Affendi Mohd Shafri
Co-Supervisor

Ahmad Hafiz Zulkifly
Co-Supervisor

Hazrina Ab Hadi
Internal Examiner

Mohd Cairul Iqbal Mohd Amin
External Examiner

Peh Kok Kiang
External Examiner

Zarina Zainuddin
Chairman

DECLARATION

I hereby declare that this thesis is the result of my own investigation, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Ahmad Fahmi Harun Ismail

Signature

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH

DEVELOPMENT, *IN-VITRO* AND *IN-VIVO* EVALUATION OF
GENTAMICIN AND NIGELLA SATIVA OIL PLGA
MICROSPHERES

I declare that the copyright holders of this dissertation are jointly owned by the student and IIUM.

Copyright © 2017 Ahmad Fahmi Harun Ismail and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Ahmad Fahmi Harun Ismail

.....
Signature

.....
Date

..for you, mom..

ACKNOWLEDGEMENTS

Praises be to Almighty Allah for His endless blessings. Peace be upon the mighty Prophet Muhammad (PBUH). Alhamdulillah I managed to complete my study. It has been a very long 4 years through thick and thin, ups and downs, sweat, blood and tears. Alhamdulillah.

My highest gratitude goes to Almighty Allah as for His blessings and will, I managed to go through all the obstacles and challenges during this 4 years. It would be a lie if I said never for once that thought came to my mind asking me to stop and quit. But when everything has gone down, I know that He wants me to look up and keep pushing. All praises belong to Him.

People say teachers are not angels, but they are the next best thing. I would like to thank my teachers as well as my supervisor, Assoc. Prof. Dr. Farahidah Mohamed for giving me guidance and ideas whenever I needed ones. And to my co-supervisors, Asst. Prof. Dr. Mohd Affendi Mohd Shafri and Prof. Dr. Ahmad Hafiz Zulkifly for keeping me on track whenever I went off wondering around.

To my biggest inspiration, my family, my wife Nurul Azyana and my kids. Thank you for the understanding and sacrifices during this long period of time. Above all, my gratitude goes to my parents, especially my late mother. God loves you more.

And not to forget, all my friends, my lab mates, all the supporting staffs, the science officers, who were giving me endless technical supports in the labs. I could not finish this study without you guys. Thank you so much.

"The acknowledgement of our weakness is the first step to the
endless world of knowledge"

TABLE OF CONTENTS

Abstract	vii
Abstract in Arabic	viii
Approval page	x
Declaration	xi
Copyright Page.....	xii
Acknowledgements	xiv
Table of Contents	xv
List of Tables	xviii
List of Figures	xx
List of Abbreviations	xxvii
CHAPTER ONE: THE OVERVIEW	1
1.1 Introduction.....	1
1.2 Research Background	2
1.3 Literature Review	5
1.3.1 Development of Controlled Release Drug	5
1.3.2 Poly (lactic-co-glycolic acid) (PLGA): The Overview	12
1.3.3 Gentamicin and Aminoglycosides	21
1.3.4 <i>Nigella sativa</i> and Its Potentials.....	29
1.3.5 Osteomyelitis	37
1.3.6 Animal Models for Osteomyelitis.....	41
1.4 Problem Statement.....	47
1.5 Objectives	48
CHAPTER TWO: PHYSICOCHEMICAL CHARACTERIZATION AND COMPATIBILITY STUDY OF N. SATIVA OIL AND GENTAMICIN	49
2.1 Introduction.....	49
2.2 Chemicals and Materials.....	50
2.3 Compatibility Study Pre and Post Gamma Irradiation	51
2.3.1 Sample Preparations.....	51
2.3.2 Gamma Irradiation	51
2.3.3 High Performance Liquid Chromatography (HPLC).....	52
2.3.4 Gas Chromatography-Mass Spectroscopy (GC-MS).....	53
2.3.5 Fourier Transform Infrared Spectroscopy (FTIR)	55
2.3.6 Differential Scanning Calorimetry (DSC)	56
2.3.7 Thin Layer Chromatography (TLC)	58
2.3.8 Surface & Interfacial Tension	59
2.3.9 <i>In-vitro</i> Cell Culture Study	61
2.4 Results and Discussion	66
2.5 Conclusion	101
CHAPTER THREE: ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF GENTAMICIN AND NSO MICROSPHERES.....	103
3.1 Introduction.....	103
3.2 Method Development and Validation For Gentamicin Microspheres....	106

3.2.1	Materials.....	106
3.2.2	Experimental Methods	106
3.2.3	Method Development and Validation for Gentamicin.....	110
3.3	Method development and validation for NSO Microspheres	113
3.3.1	Materials.....	113
3.3.2	Experimental Methods	113
3.3.3	Method Development and Validation	114
3.4	Results and Discussion	118
3.4.1	Gentamicin: Particle Size Distribution and Encapsulation Efficiency.....	118
3.4.2	Gentamicin Efficacy for Post Microparticle Fabrication	122
3.5	Analytical method validation.....	125
3.5.1	Gentamicin: Specificity.....	125
3.5.2	Gentamicin: Linearity and Range	127
3.5.3	Gentamicin: Accuracy and Precision.....	129
3.5.4	Gentamicin: Limit of Detection (LOD) and Limit of Quantification (LOQ)	133
3.5.5	Gentamicin: Simplified Robustness.....	133
3.5.6	NSO: Particle Size Distribution and Encapsulation Efficiency	135
3.6	Analytical Method Validation	139
3.6.1	NSO: Specificity	139
3.6.2	NSO: Linearity and Standard Curve	142
3.6.3	NSO: Accuracy and Precision.....	144
3.6.4	NSO: Limit of Detection (LOD) and Limit of Quantification (LOQ)	148
3.6.5	NSO: Simplified Robustness	148
3.7	Conclusion	151

CHAPTER FOUR: PLGA MICROSPHERES FORMULATIONS AND CHARACTERIZATIONS152

4.1	Introduction.....	152
4.2	Materials and Chemicals.....	152
4.3	Methodology.....	153
4.3.1	Fabrication of Gentamicin Microspheres.....	153
4.3.2	Fabrication of NSO Microspheres	156
4.4	Characterization of The Microspheres.....	159
4.4.1	Particle Size Distribution	159
4.4.2	Zeta Potentials.....	159
4.4.3	External Morphology	160
4.4.4	Encapsulation Efficiency	160
4.4.5	<i>In-vitro</i> Release Profile	162
4.4.6	Statistical Analysis.....	163
4.5	Results and Discussion	164
4.6	Conclusion	197

CHAPTER FIVE: PRE CLINICAL EFFICACY STUDY OF COMPRESSED GENTAMICIN AND NSO PLGA MICROSPHERES IN OSTEOMYELITIC RABBIT199

5.1	Introduction.....	199
-----	-------------------	-----

5.2 Materials and Chemicals.....	201
5.2.1 Animals	202
5.3 Methodology.....	202
5.3.1 Inoculum Preparation.....	202
5.3.2 Preparation of Compressed Microspheres	203
5.3.3 Surgical Procedure and Animal Healthcare	203
5.3.4 White Blood Cells (WBC) Differential Count.....	206
5.3.5 X-Rays Imaging	206
5.3.6 Post Surgical Bacterial Culture	208
5.3.7 Statistical Analysis	208
5.4 Results and Discussion	209
5.5 Conclusion	235
CHAPTER SIX: GENERAL CONCLUSION	236
6.1 The Discussion.....	236
6.2 General Conclusion	241
6.3 Recommendations for Future Work	243
REFERENCES.....	245
PUBLICATIONS	264
CONFERENCES	265
APPENDIX I	266
APPENDIX II.....	267

LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
1.1	Decreasing order of nephrotoxic aminoglycosides used systemically (Decker & Molitoris, 2008)	25
1.2	Some of the potentials of the plant active ingredients, the oil extracts and the seeds of <i>N. sativa</i>	32
2.1	The description of four samples for surface tension evaluation	60
2.2	The treatments assigned for the cell viability study (MTT assay). Each treatment was done in triplicate (n=3). For the fusion group, gentamicin and NSO were denoted as (G) and (N) respectively	63
2.3	Four main compounds detected by GC-MS from the esterification of the NSO sample for both pre and post Gamma irradiation	72
2.4	The surface tension and the density of four gentamicin, NSO and the fusion samples (as described in Table 2.1) evaluated based on the pre and post Gamma irradiation. Note that for Sample 3 (Pre Gamma), the measurement could not be obtained due to the slurry state of the mixture after being homogenized. * indicated that there was significant difference when analysed using one-way ANOVA, post-hoc Tukey's test ($p < 0.05$).	92
3.1	The nine formulations of the microspheres based on the polymer blends. The PLGA ratio indicated the amount of the polymer used according to the intrinsic viscosities out of 100 mg of total PLGA blends. The amount of gentamicin loaded for each formulation was 100 mg each	108
3.2	The nine formulations of the microspheres based on the polymer blends. The PLGA ratio indicated the amount of the polymer used according to the intrinsic viscosities out of 100 mg of total PLGA blends. The amount of NSO loaded for each formulation was 100 mg each	115
3.3	The average diameters of zone of inhibition according to the formulations (n=3) . No significant difference was observed when analysed one-way ANOVA, post-hoc Tukey's test, ($p < 0.05$)	124
3.4	The intermediate precision was obtained by using UV-spectrophotometry for gentamicin-ninhydrin complex	130
3.5	The repeatability study (intraday precision) by using UV-spectrophotometry	131

3.6	The accuracy of the method was evaluated based on the average recovery and the %RSD value of each concentration	132
3.7	The correlation coefficient R^2 values and the linear equations	134
3.8	Interday precision of N. sativa oil recorded using UV-spectrophotometry	145
3.9	Intraday precision of N. sativa oil determined by UV-spectrophotometry	146
3.10	Data evaluation of accuracy study for NSO using UV-spectroscopy	147
4.1	The 27 formulations of the microspheres based on the polymer blends. The PLGA ratio indicated the amount of the polymer used according to the intrinsic viscosities out of 100 mg of total PLGA blends. The amount of gentamicin loaded for each formulation was 100 mg each	155
4.2	The 27 formulations of the microspheres based on the polymer blends. The PLGA ratio indicated the amount of the polymer used according to the intrinsic viscosities out of 100 mg of total PLGA blends	158
4.3	The size distributions with span values and the zeta potentials of the fabricated gentamicin microspheres represented as mean of triplicate readings (n=3) with standard deviations (S.D)	166
4.4	The size distributions with span values and the zeta potentials of the fabricated NSO microspheres represented as mean of triplicate readings (n=3) with standard deviations (S.D)	167
4.5	The thickness, diameter and hardness of the compressed gentamicin and NSO microspheres discs with and without kaolin (n=3). The data indicated kaolin reduced the hardness of the compressed microspheres loaded with gentamicin notably	185
4.6	The equations and the correlation coefficients (R^2) of the release profile based on the selected formulations of gentamicin microspheres. The data is tabulated according to the Zero-order, First-order and Higuchi kinetic equations	195
4.7	The equations and the correlation coefficients (R^2) of the release profile based on the selected formulations of NSO microspheres. The data is tabulated according to the Zero-order, First-order and Higuchi kinetic equations	196
5.1	The normal range for the white blood cell (WBC) differential count based on the individual components (Moore, 2000)	222

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
1.1	The structure of (a) polylactic acid, (b) polyglycolic acid and (c) poly (lactic-co-glycolic acid) as described by Zhou and Bhaduri, (2012)	14
1.2	(a) Formation of PLGA polymer from lactic acid and glycolic acid and (b) degradation of PLGA chain into its monomers via hydrolysis (Bouissou & Walle, 2006)	15
1.3	Molecular structure of thymoquinone (Ravindran et al., 2010)	36
1.4	Osteomyelitic condition in goat (Patel et al., 2009)	45
2.1	The arrangement of the 96-well plates based on the group treatments. CM is complete media, D is DMSO and BP is blank particles	64
2.2	The HPLC chromatogram for (A) pre gamma irradiation and (B) post gamma irradiation of gentamicin. The samples were injected at 0.025 mg/mL	68
2.3	The HPLC chromatogram of gentamicin-ninhydrin complex. The spiking was done by injecting (A) 0.05 mg/mL and (B) 0.1 mg/mL of gentamicin-ninhydrin complex	69
2.4	The overlay chromatogram of NSO for pre and post Gamma irradiation. The red line indicates the pre Gamma chromatogram and the blue line indicates the post Gamma chromatogram	73
2.5	The overlay chromatogram of NSO (FAMES left undisturbed for three days before injected into GC-MS). The black line is for the pre Gamma irradiation and the blue line is for the post Gamma irradiation	74
2.6	The fatty acids identified based on the data obtained from NIST Mass Spectrometry Data Center corresponded to the peaks obtained	76
2.7	FTIR spectra for gentamicin pre and post gamma irradiation	79
2.8	FTIR spectra for NSO pre and post gamma irradiation	80
2.9	FTIR spectra for the fusion of gentamicin and NSO pre and post gamma irradiation	81
2.10	The signature thermal event for gentamicin (marked with A) which was around 240 °C to 250 °C both for pre and post Gamma irradiation	85

2.11	The signature thermal event for NSO (marked with A) which was around -34 °C both for pre and post Gamma irradiation	86
2.12	The thermogram of the fusion in comparison to the thermogram gentamicin and NSO. A1 and A2 marked the signature thermal event between NSO and the fusion. B1 and B2 marked the signature thermal event between gentamicin and the fusion	87
2.13	TLC plate showing the migration of gentamicin-ninhydrin complex. The pre (A) and post (B) gamma irradiation of gentamicin-ninhydrin complex indicated the similar Rf values	89
2.14	TLC plate showing the migration of the spots of NSO. The pre (A) and post (B) gamma irradiation of NSO indicated the similar Rf values	90
2.15	The percentage of cell viability for 5 different concentrations of gentamicin based on the MTT assay. The viability percentage of untreated cells was assumed as 100%. The asterisk (*) shows the groups with significant difference when compared with the untreated group (One-way ANOVA, post-hoc Tukey's test, $p < 0.05$)	96
2.16	The percentage of cell viability for 5 different concentrations of NSO based on the MTT assay. The viability percentage of untreated cells was assumed as 100%. The asterisk (*) shows the groups with significant difference when compared with the untreated group (One-way ANOVA, post-hoc Tukey's test, $p < 0.05$)	97
2.17	The percentage of cell viability for 5 different concentrations (Table 2.2) of the fusion between gentamicin and NSO based on the MTT assay. The viability percentage of untreated cells was assumed as 100%. The asterisk (*) shows the groups with significant difference when compared with the untreated group (One-way ANOVA, post-hoc Tukey's test, $p < 0.05$)	98
3.1	Size distribution for gentamicin microspheres according to formulation. Difference letters indicated significant difference in the mean size distributions among the formulations (One-way ANOVA, post-hoc Tukey's test, $p < 0.05$)	120
3.2	Span value for gentamicin microspheres size distribution according to formulation	120
3.3	Encapsulation efficiency of the gentamicin loaded microspheres based on the formulations employed. Difference letters indicated significant difference in the mean encapsulation efficiency among the formulations (One-way ANOVA, post-hoc Tukey's test, $p < 0.05$)	121

3.4	The zone of inhibition for some of the formulations (F2, F6 and F7) gentamicin against <i>Staphylococcus aureus</i> and the positive control (marked as G.100)	123
3.5	The UV wavelength scanning spectrum of PLGA, ninhydrin (NH) reagent, and gentamicin-ninhydrin complex for specificity	126
3.6	The standard curve constructed for linearity study of the gentamicin consisted of 6 known concentrations. Each reading was done in triplicate (n=3)	128
3.7	Average size distribution of NSO microspheres (n=3) according to the formulations. No significant difference was observed among the formulations (One-way ANOVA, post-hoc Tukey's test, $p < 0.05$)	136
3.8	Span value for NSO microspheres size distribution according to formulation	136
3.9	Encapsulation efficiency of <i>N. sativa</i> oil microspheres done in triplicate (n=3). Statistical analysis (One-way ANOVA, post-hoc Tukey's test, $p < 0.05$) revealed that no significant difference among formulations with the same denomination (<i>a, b, c</i>)	137
3.10	Response surface plots for particle size distribution (A) and encapsulation efficiency (B) of NSO based on MW blends and MW ratio	138
3.11	The highest detection of <i>N. sativa</i> oil using spectrophotometry at 271 nm (black) and the peak for PLGA (blue)	140
3.12	The wavelength scan of NSO for post fabrication microspheres based on the formulations used	141
3.13	The standard curve or linear regression of <i>N. sativa</i> oil using spectrophotometry	143
3.14	The single-solvent system of NSO standard curve was constructed using chloroform. This 6 known concentrations standard curve was constructed with the R^2 of 0.996	149
3.15	The standard curve of NSO constructed by different analyst with 6 known concentrations. The standard curve was constructed with the value of R^2 of 0.998	150
4.1	Schematic diagram of the fabrication procedure of the gentamicin microspheres. The oil phase (#), the Aqueous 1 (€), the primary emulsion (Ω) and the secondary emulsion (Δ)	154
4.2	The schematic diagram of the procedure to fabricate the NSO microspheres. The oil phase (#), the aqueous phase (€) and the primary emulsion (Ω)	157

- 4.3 Encapsulation efficiency expressed in percentage for microspheres loaded with gentamicin according to the formulations assigned. The lowest encapsulation efficiency was recorded by Formulation 3 with $17.02\% \pm 1.84$ and the highest was by Formulation 6 with $83.40\% \pm 4.22$. All readings were made in triplicate (n=3) 172
- 4.4 The antimicrobial activity of gentamicin was proven for post fabrication process against *S. aureus*. Only five formulations with the best drug loading percentage were tested (F4, F6, F9, F17 and F21). A known concentration of gentamicin (100 mg/mL) was used as a control group, noted with G.100 in the figure 173
- 4.5 Five highest percentage of encapsulation efficiency for gentamicin microspheres according to the formulations. Only Formulation 4 and 6 showed a significant difference when statistically analysed using ANOVA (post hoc Dunnett Test) at 95% confidence level ($P < 0.05$) (marked with asterisk and bar) All readings were done in triplicate with SD as the error bars (n=3) 174
- 4.6 The encapsulation efficiency of 27 formulations used in fabricating NSO loaded PLGA microspheres. Formulation 26 had the lowest encapsulation efficiency ($34.56\% \pm 8.1$) and the highest was recorded by Formulation 20 with $73.42\% \pm 2.14$. All readings were made in triplicate (n=3) 177
- 4.7 Five highest percentage of encapsulation efficiency for NSO loaded PLGA microspheres according to the formulations. Statistical analysis using ANOVA (post hoc Dunnett Test) with 95% confidence level ($p < 0.05$), no significant difference was observed between all those five formulations. All readings were done in triplicate with SD represented by error bars (n=3) 178
- 4.8 SEM images of gentamicin microspheres for Formulation 4, 6, 9, 17 and 21 labelled with A, B, C, D and E respectively. All scale bars are equivalent to 10 μm . Formulation 17 indicated dimpled microspheres while the rest with smooth rounded shape 180
- 4.9 SEM images of NSO loaded microspheres for Formulation 6, 14, 15, 17 and 20 labelled with A, B, C, D and E respectively. All scale bars are equivalent to 10 μm . All five formulations exhibited smooth external morphology with minor irregularity in shape of the microspheres 181
- 4.10 The Quick Press Pallet Kit (A) and the shape of the compressed microspheres after the compression (B) 184
- 4.11 The degree of disintegration of compressed discs after being immersed in distilled water for 15 minutes. The kaolin disc (A), the gentamicin microspheres disc (B), the NSO microspheres disc (C), the disc of gentamicin microspheres added with 4.5 mg of kaolin (D)

	and the disc of NSO microspheres added with 4.5 mg of kaolin (E). These images showing the ability of kaolin to facilitate the process of disintegration of the compressed microspheres	187
4.12	Overlaid release patterns for gentamicin microspheres in comparison between powdered and compressed forms for Formulation 4, 6, 9, 17 and 21. The highest amount released was recorded by compressed microspheres for Formulation 21 and the lowest was Formulation 4 (powdered). One-way ANOVA (post hoc Tukey's test, $p < 0.05$) was performed for day 28. Asterisks (*) indicated significant difference when compared with the highest release (Compressed F21)	190
4.13	Overlaid release patterns for NSO microspheres in comparison between powdered and compressed forms for Formulation 6, 14, 15, 17 and 20. The highest amount released for NSO microspheres recorded for Formulation 14 (powdered) and the lowest was Formulation 20 (compressed). One-way ANOVA (post hoc Tukey's test, $p < 0.05$) was performed for day 28. Asterisks (*) indicated significant difference when compared with the highest release (Powdered F14)	191
5.1	The proximal region of the tibia showing the imaginary axial line (dotted black line) and the 3 points (red crosses) where the pixel intensity was measured	207
5.2	Time line for the overall flow of the animal study showing the main evaluations and data collection events. The events were carried out based on the assigned weeks as denoted with T in the time line	211
5.3	X-ray images of control group (no treatment) were compared with the images of healthy tibiae. White arrows indicate the radiolucency of the proximal tibiae in the subchondral region. N1 to N4 were images taken from normal healthy rabbits. A1 to A4 were images taken at week 3 and B1 to B4 were the images taken at week 6	212
5.4	The X-ray images of the group given the compressed gentamicin microspheres for the treatment. A1 to A4 and B1 to B4 were the X-rays taken on week 3 and week 6 respectively showing no sign of demarcation on the proximal region of the tibiae	213
5.5	The X-ray images of the group given the compressed NSO microspheres for the treatment. A1 to A4 and B1 to B4 were the X-rays taken on week 3 and week 6 respectively showing no sign of demarcation on the proximal region of the tibiae	214
5.6	The X-ray images of the group given the compressed gentamicin and NSO microspheres (fusion) for the treatment. A1 to A4 and B1 to B4 were the X-rays taken on week 3 and week 6 respectively showing no sign of demarcation on the proximal region of the tibiae	215

5.7	The comparison of pixel intensity between the normal tibiae and the control group (no treatment) as well as the gentamicin, NSO and Fusion treatment groups for week 3 and week 6. The black and blue lines are the indication for significant difference at 95% confidence level ($P<0.05$) when tested using one-way ANOVA (Dunnett's Test)	218
5.8	Differential count for lymphocyte based on the group treatments and the week the readings were taken. The red line indicated the significant difference at 95% confidence level ($P<0.05$) when tested with ANOVA (repeated measurement) with Tukey HSD was set for the Post Hoc against the control group	223
5.9	Differential count for neutrophil based on the group treatments and the week the readings were taken. The red line indicated the significant difference at 95% confidence level ($P<0.05$) when tested with ANOVA (repeated measurement) with Tukey HSD was set for the Post Hoc against the control group	224
5.10	Differential count for monocyte based on the group treatments and the week the readings were taken. The red line indicated the significant difference at 95% confidence level ($P<0.05$) when tested with ANOVA (repeated measurement) with Tukey HSD was set for the Post Hoc against the control group	225
5.11	Differential count for basophil based on the group treatments and the week the readings were taken. The data was tested with ANOVA (repeated measurement) with Tukey HSD for the Post Hoc at 95% confidence level ($P<0.05$). However, no groups had shown any significant difference as compared to the control group	226
5.12	Differential count for eosinophil based on the group treatments and the week the readings were taken. The data was tested with ANOVA (repeated measurement) with Tukey HSD for the Post Hoc at 95% confidence level ($P<0.05$). However, no groups had shown any significant difference as compared to the control group	227
5.13	The post surgical microbial study revealed that samples taken from the control group had shown the presence of bacteria colonies after being cultured for 24 hours. A1 to A4 were the samples cultured on Nutrient Agar whereas B1 to B4 were the samples cultured on Mannitol Agar	228
5.14	Agar plates randomly selected from the treatment groups showing no bacteria colonies detected after 24 hours incubation. A1, A2 and A3 were the Nutrient Agar plates corresponded to gentamicin, NSO and the fusion treatment group respectively. Whereas B1, B2 and B3 were the Mannitol Agar plates corresponded to gentamicin, NSO and the fusion treatment group respectively	229

- 5.15 The average body temperature of the rabbits based on the groups and the week of the measurements taken. The red lines were showing the significant difference at 95% confidence level ($P < 0.05$) when tested with ANOVA (repeated measurement) with Tukey HSD was set for Post Hoc as compared to normal body temperature. Each readings were done in triplicate ($n=3$) with SD was represented by error bars. All readings were made in triplicate ($n=3$) 233
- 5.16 The average body weight of the rabbits based on the groups and the week of the measurements taken. However, no significant difference was observed for all groups when tested with ANOVA (repeated measurement) with Tukey HSD was set for Post Hoc ($P < 0.05$) as compared with the normal body weight. Each readings were done in triplicate ($n=3$) with SD was represented by error bars. All reading were made in triplicate ($n=3$) 234

LIST OF ABBREVIATIONS

ATCC	American Type Culture Collection
BSA	Bovine Serum Albumin
CTAB	Cetyl trimethylammonium bromide
CFU	Colony Forming Unit
DSC	Differential Scanning Calorimeter
DCM	Dichloromethane
DMSO	Dimethylsulfoxide
FTIR	Fourier Transform Infrared Spectroscopy
GC-MS	Gas Chromatography-Mass Spectrometry
HLB	Hydrophile-Lyphophile Balance
HPLC	High Performance Liquid Chromatography
LE	Drug Loading Efficiency
LOD	Limit of Detection
LOQ	Limit of Quantification
MAA	Methacrylic Acid
MSDS	Material Safety Data Sheet
MIC	Minimum Inhibition Concentration
MTT	Microculture Tetrazolium Assay
NSO	<i>Nigella sativa</i> oil
O.D.	Optical Density
PBS	Phosphate Buffer Saline
PMMA	polymethylmethacrylate
PDLA	poly D-lactic acid
PLLA	poly L-lactic acid
PGA	polyglycolic acid
PLA	poly(D,L-lactic) acid
PVA	Poly vinyl alcohol
PLGA	Poly (D,L-lactide-co-glycolide) acid
Rf	Retention Factor
S.D	Standard Deviation
SEM	Scanning Electron Microscopy
T_g	Glass Transition Temperature
TLC	Thin Layer Chromatography
US FDA	United State Food Drug Administration
MW	Molecular Weight
WBC	White Blood Cell

CHAPTER ONE

THE OVERVIEW

1.1 INTRODUCTION

The discovery of penicillin as one of the early most antibiotics in 1940s has become the most remarkable breakthrough in medical history. This huge discovery has later become the starting point for more discoveries of antibiotics originated from microbes especially from the members of actinomycetes and fungi (Abed & Couvreur, 2014; Peláez, 2006). The world nowadays has benefited healthy living and enjoyed the control over the infectious diseases for many years. The quality of life has drastically improved and more new methods of combating the infections have been introduced.

However, many bacteria have shown to develop resistance towards the antibiotics available. Many scientific reports have raised the concern of inadequate availability of new antibiotics to address the problem posed by the bacterial resistance that has been growing by day (Bradley et al., 2007; Baucher et al., 2009; Freire-Moran et al., 2011). Resistant and multi resistant bacteria are no doubt posing huge danger to everyone. The fact that their resistance genes can be spread easily, faster and further has further made the emergence of antibiotic resistance to become more complicated (Cars et al., 2011)

Although the requirement for new compounds to fight the infectious organisms is growing as the result to the increase number of antibiotic-resistant pathogens, surprisingly just a handful of new antibiotics have been approved for the clinical use in the past decades (Wright, 2014).

This situation that has been called an "apocalyptic" threat to the mankind has drawn a huge concern amongst the scientists while the pharmaceutical sectors seem to

unable to counter the threat effectively (Wright, 2014). Other than in favor to the large libraries of synthetic molecules, the difficulties to identify new natural compounds that possess antimicrobial property have become the reason for the pharmaceutical industry to focus more on developing new method of administrating the existing drugs to increase the efficacy.

The development of new agents with antimicrobial property is much needed when the discovery of new antimicrobial natural compounds could not keep up with the resistance which is emerging in a very fast manner. The development in drug discovery and pharmaceutical technology has proven that natural compounds are no longer the only citizen in the world of antibiotics. The formula modification and combination with other potent existing drugs has proven to be the most efficient way to develop novel drugs active against resistant strains (Fernebro, 2011).

The novel drug combinations coupled with the new strategies in controlling the release of the drugs at the specific area are amongst the factors which improve the efficacy of the existing antibiotics. Many formulations are being developed by taking into consideration the effectiveness and the optimization of the drugs by manipulating the release patterns and the synergistic effect obtained through combinations with foreign compounds. Despite of having such "apocalyptic" threat, the new drug development and formulation seem to give a new opening to huge opportunities in solving the crisis faced by healthcare personnel and scientists around the world.

1.2 RESEARCH BACKGROUND

Staphylococcus aureus is one of the bacteria that are responsible for most medical infectious cases especially related to the bone. In general, the most isolated pathogen from the patients in the field of orthopedics was *S. aureus* (Nelson & Williams, 2014;